Acquired Hemophilia A: Current Guidance and Experience from Clinical Practice

References

• Collins PW, Hirsch S, Baglin TP, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood. 2007;109(5):1870–1877. doi:10.1182/blood-2006-06-029850
   PubMed Web of Science ®Google Scholar
• Knoebl P, Marco P, Baudo F, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012;10(4):622–631. doi:10.1111/j.1538-7836.2012.04654.x
   PubMed Web of Science ®Google Scholar
• Franchini M, Zaffanello M, Lippi G. Acquired hemophilia in pediatrics: a systematic review. Pediatr Blood Cancer. 2010;55(4):606–611. doi:10.1002/pbc.22657
   PubMed Web of Science ®Google Scholar
• Charlebois J, Rivard GE, St-Louis J. Management of acquired hemophilia A: review of current evidence. Transfus Apher Sci. 2018;57(6):717–720. doi:10.1016/j.transci.2018.10.011
   PubMed Web of Science ®Google Scholar
• Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost. 1981;45(3):200–203. doi:10.1055/s-0038-1650169
   PubMed Web of Science ®Google Scholar
• Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003;121(1):21–35. doi:10.1046/j.1365-2141.2003.04162.x
   PubMed Web of Science ®Google Scholar
• Tay L, Duncan E, Singhal D, et al. Twelve years of experience of acquired hemophilia A: trials and tribulations in South Australia. Semin Thromb Hemost. 2009;35(8):769–777. doi:10.1055/s-0029-1245109
   PubMed Web of Science ®Google Scholar
• Borg JY, Guillet B, Le Cam-duchez V, Goudemand J, Levesque H, Group SS. Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l’Hemophilie Acquise) registry. Haemophilia. 2013;19(4):564–570. doi:10.1111/hae.12138
   PubMed Web of Science ®Google Scholar
• Huang SY, Tsay W, Lin SY, Hsu SC, Hung MH, Shen MC. A study of 65 patients with acquired hemophilia A in Taiwan. J Formos Med Assoc. 2015;114(4):321–327. doi:10.1016/j.jfma.2013.01.006
   PubMed Web of Science ®Google Scholar
• Tiede A, Klamroth R, Scharf RE, et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. Blood. 2015;125(7):1091–1097. doi:10.1182/blood-2014-07-587089
   PubMed Web of Science ®Google Scholar
• Franchini M, Gandini G, Di Paolantonio T, Mariani G. Acquired hemophilia A: a concise review. Am J Hematol. 2005;80(1):55–63. doi:10.1002/ajh.20390
   PubMed Web of Science ®Google Scholar
• Sborov DW, Rodgers GM. Acquired hemophilia a: a current review of autoantibody disease. Clin Adv Hematol Oncol. 2012;10(1):19–27.
   PubMedGoogle Scholar
• Gunel Karaburun IE, Kayki G, Aytac SS, Celik HT, Gumruk F, Yigit S. Transplacental hemophilia A and prophylactic treatment with intravenous immunoglobulin and recombinant factor VIIa in the newborn period: a case report. Blood Coagul Fibrinolysis. 2021;32(2):151–154. doi:10.1097/MBC.0000000000000978
   PubMed Web of Science ®Google Scholar
• Lulla RR, Allen GA, Zakarija A, Green D. Transplacental transfer of postpartum inhibitors to factor VIII. Haemophilia. 2010;16(1):14–17. doi:10.1111/j.1365-2516.2009.02049.x
   PubMed Web of Science ®Google Scholar
• Pardos-Gea J, Fernandez-Diaz N, Parra R, Cortina V, Altisent C. Diagnostic delay in acquired haemophilia: analysis of causes and consequences in a 20-year Spanish cohort. Haemophilia. 2018;24(3):e163–e166. doi:10.1111/hae.13499
   PubMed Web of Science ®Google Scholar
• Tiede A, Collins P, Knoebl P, et al. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica. 2020;105(7):1791–1801. doi:10.3324/haematol.2019.230771
   PubMed Web of Science ®Google Scholar
• de Maistre E, Wahl D, Perret-Guillaume C, et al. A chromogenic assay allows reliable measurement of factor VIII levels in the presence of strong lupus anticoagulants. Thromb Haemost. 1998;79(1):237–238. doi:10.1055/s-0037-1614254
   PubMed Web of Science ®Google Scholar
• Chandler WL, Ferrell C, Lee J, Tun T, Kha H. Comparison of three methods for measuring factor VIII levels in plasma. Am J Clin Pathol. 2003;120(1):34–39. doi:10.1309/C8T8-YNB4-G3W4-5PRF
   PubMed Web of Science ®Google Scholar
• Blanco AN, Cardozo MA, Candela M, Santarelli MT, Perez Bianco R, Lazzari MA. Anti-factor VIII inhibitors and lupus anticoagulants in haemophilia A patients. Thromb Haemost. 1997;77(4):656–659. doi:10.1055/s-0038-1656029
   PubMed Web of Science ®Google Scholar
• Taher A, Abiad R, Uthman I. Coexistence of lupus anticoagulant and acquired haemophilia in a patient with monoclonal gammopathy of unknown significance. Lupus. 2003;12(11):854–856. doi:10.1191/0961203303lu463cr
   PubMed Web of Science ®Google Scholar
• Seethala S, Collins NP Jr, Comerci G Jr. An unusual etiology for elevation of Activated Partial Thromboplastin Time (aPTT) in SLE: acquired hemophilia and lupus anticoagulant. Case Rep Hematol. 2013;2013:521785. doi:10.1155/2013/521785
   PubMedGoogle Scholar
• Kasper CK. Measurement of factor VIII inhibitors. Prog Clin Biol Res. 1984;150:87–98.
   PubMedGoogle Scholar
• Gawryl MS, Hoyer LW. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood. 1982;60(5):1103–1109. doi:10.1182/blood.V60.5.1103.1103
   PubMed Web of Science ®Google Scholar
• Mahendra A, Padiolleau-Lefevre S, Kaveri SV, Lacroix-Desmazes S. Do proteolytic antibodies complete the panoply of the autoimmune response in acquired haemophilia A? Br J Haematol. 2012;156(1):3–12. doi:10.1111/j.1365-2141.2011.08890.x
   PubMed Web of Science ®Google Scholar
• Hoyer LW, Scandella D. Factor VIII inhibitors: structure and function in autoantibody and hemophilia A patients. Semin Hematol. 1994;31(2 Suppl 4):1–5.
   PubMed Web of Science ®Google Scholar
• Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost. 1995;73(2):247–251. doi:10.1055/s-0038-1653759
   PubMed Web of Science ®Google Scholar
• Boylan B, Miller CH. Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels. Haemophilia. 2018;24(3):487–491. doi:10.1111/hae.13435
   PubMed Web of Science ®Google Scholar
• Hofbauer CJ, Whelan SF, Hirschler M, et al. Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. Blood. 2015;125(7):1180–1188. doi:10.1182/blood-2014-09-598268
   PubMed Web of Science ®Google Scholar
• Whelan SF, Hofbauer CJ, Horling FM, et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood. 2013;121(6):1039–1048. doi:10.1182/blood-2012-07-444877
   PubMed Web of Science ®Google Scholar
• Reipert BM, Gangadharan B, Hofbauer CJ, et al. The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development. Blood Adv. 2020;4(22):5785–5796. doi:10.1182/bloodadvances.2020002731
   PubMed Web of Science ®Google Scholar
• Reding MT, Lei S, Lei H, Green D, Gill J, Conti-Fine BM. Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients. Thromb Haemost. 2002;88(4):568–575. doi:10.1055/s-0037-1613257
   PubMed Web of Science ®Google Scholar
• Tiede A, Hofbauer CJ, Werwitzke S, et al. Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study. Blood. 2016;127(19):2289–2297. doi:10.1182/blood-2015-09-672774
   PubMed Web of Science ®Google Scholar
• Wootla B, Dasgupta S, Dimitrov JD, et al. Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia. J Immunol. 2008;180(11):7714–7720. doi:10.4049/jimmunol.180.11.7714
   PubMed Web of Science ®Google Scholar
• Scandella DH, Nakai H, Felch M, et al. In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic. Thromb Res. 2001;101(5):377–385. doi:10.1016/s0049-3848(00)00418-7
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Zeitler H, Pavlova A. Genetic markers in acquired haemophilia. Haemophilia. 2010;16(Suppl 3):41–45. doi:10.1111/j.1365-2516.2010.02259.x
   PubMed Web of Science ®Google Scholar
• Pavlova A, Diaz-Lacava A, Zeitler H, et al. Increased frequency of the CTLA-4 49 A/G polymorphism in patients with acquired haemophilia A compared to healthy controls. Haemophilia. 2008;14(2):355–360. doi:10.1111/j.1365-2516.2007.01618.x
   PubMed Web of Science ®Google Scholar
• Pavlova A, Zeitler H, Scharrer I, Brackmann HH, Oldenburg J. HLA genotype in patients with acquired haemophilia A. Haemophilia. 2010;16(102):107–112. doi:10.1111/j.1365-2516.2008.01976.x
   PubMed Web of Science ®Google Scholar
• Tiede A, Eisert R, Czwalinna A, Miesbach W, Scharrer I, Ganser A. Acquired haemophilia caused by non-haemophilic factor VIII gene variants. Ann Hematol. 2010;89(6):607–612. doi:10.1007/s00277-009-0887-3
   PubMed Web of Science ®Google Scholar
• Reding MT, Wu H, Krampf M, et al. Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects. Thromb Haemost. 2000;84(4):643–652. doi:10.1055/s-0037-1614081
   PubMed Web of Science ®Google Scholar
• Tiede A, Giangrande P, Teitel J, et al. Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: a global expert consensus statement. Haemophilia. 2019;25(6):969–978. doi:10.1111/hae.13844
   PubMed Web of Science ®Google Scholar
• Franchini M, Lippi G. Acquired factor VIII inhibitors. Blood. 2008;112(2):250–255. doi:10.1182/blood-2008-03-143586
   PubMed Web of Science ®Google Scholar
• Kruse-Jarres R, Kempton CL, Baudo F, et al. Acquired hemophilia A: updated review of evidence and treatment guidance. Am J Hematol. 2017;92(7):695–705. doi:10.1002/ajh.24777
   PubMed Web of Science ®Google Scholar
• Baudo F, Collins P, Huth-Kuhne A, et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood. 2012;120(1):39–46. doi:10.1182/blood-2012-02-408930
   PubMed Web of Science ®Google Scholar
• Fisher C, Mo A, Warrillow S, Smith C, Jones D. Utility of thromboelastography in managing acquired Factor VIII inhibitor associated massive haemorrhage. Anaesth Intensive Care. 2013;41(6):799–803. doi:10.1177/0310057X1304100617
   PubMed Web of Science ®Google Scholar
• Holmstrom M, Tran HT, Holme PA. Combined treatment with APCC (FEIBA(R)) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A–a two-centre experience. Haemophilia. 2012;18(4):544–549. doi:10.1111/j.1365-2516.2012.02748.x
   PubMed Web of Science ®Google Scholar
• Takedani H, Shima M, Horikoshi Y, et al. Ten-year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan. Haemophilia. 2015;21(3):374–379. doi:10.1111/hae.12611
   PubMed Web of Science ®Google Scholar
• Taparia M, Cordingley FT, Leahy MF. Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia. Eur J Haematol. 2002;68(5):307–309. doi:10.1034/j.1600-0609.2002.01607.x
   PubMed Web of Science ®Google Scholar
• Kruse-Jarres R, St-Louis J, Greist A, et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia. 2015;21(2):162–170. doi:10.1111/hae.12627
   PubMed Web of Science ®Google Scholar
• Ellsworth P, Chen S-L, Wang C, Key NS, Ma A. Rituximab monotherapy is effective for inhibitor eradication with concomitant porcine factor viii followed by emicizumab for bleed control in acquired hemophilia A. Blood. 2021;138:348. doi:10.1182/blood-2021-154207
   Web of Science ®Google Scholar
• Martin K, Kasthuri R, Mooberry MJ, Chen SL, Key NS, Ma AD. Lower doses of recombinant porcine factor VIII maintain excellent haemostatic efficacy. Haemophilia. 2016;22(6):e549–e551. doi:10.1111/hae.13038
   PubMed Web of Science ®Google Scholar
• Tarantino MD, Cuker A, Hardesty B, Roberts JC, Sholzberg M. Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients. Haemophilia. 2017;23(1):25–32. doi:10.1111/hae.13040
   PubMed Web of Science ®Google Scholar
• Muto A, Yoshihashi K, Takeda M, et al. Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood. 2014;124(20):3165–3171. doi:10.1182/blood-2014-07-585737
   PubMed Web of Science ®Google Scholar
• Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18(10):1570–1574. doi:10.1038/nm.2942
   PubMed Web of Science ®Google Scholar
• Makris M, Iorio A, Lenting PJ. Emicizumab and thrombosis: the story so far. J Thromb Haemost. 2019;17(8):1269–1272. doi:10.1111/jth.14556
   PubMed Web of Science ®Google Scholar
• Dane KE, Lindsley JP, Streiff MB, Moliterno AR, Khalid MK, Shanbhag S. Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention. Res Pract Thromb Haemost. 2019;3(3):420–423. doi:10.1002/rth2.12201
   PubMed Web of Science ®Google Scholar
• Poston JN, Al-Banaa K, von Drygalski A, et al. Emicizumab for the treatment of acquired hemophilia A: a multicenter US case series. Blood. 2021;138:496. doi:10.1182/blood-2021-148040
   Web of Science ®Google Scholar
• Knoebl P, Thaler J, Jilma P, Quehenberger P, Gleixner K, Sperr WR. Emicizumab for the treatment of acquired hemophilia A. Blood. 2021;137(3):410–419. doi:10.1182/blood.2020006315
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809–818. doi:10.1056/NEJMoa1703068
   PubMed Web of Science ®Google Scholar
• Schep SJ, van Dijk WEM, Beckers EAM, et al. Treatment of acquired hemophilia A, a balancing act: results from a 27-year Dutch cohort study. Am J Hematol. 2021;96(1):51–59. doi:10.1002/ajh.26009
   PubMed Web of Science ®Google Scholar
• Pardos-Gea J, Altisent C, Parra R, Vilardell-Tarres M, Ordi-Ros J. Acquired haemophilia A. First line treatment with calcineurin inhibitors and steroid pulses: a 10-year follow-up study. Haemophilia. 2012;18(5):789–793. doi:10.1111/j.1365-2516.2012.02772.x
   PubMed Web of Science ®Google Scholar
• Obaji S, Rayment R, Collins PW. Mycophenolate mofetil as adjunctive therapy in acquired haemophilia A. Haemophilia. 2019;25(1):e59–e65. doi:10.1111/hae.13658
   PubMed Web of Science ®Google Scholar
• Lian EC, Villar MJ, Noy LI, Ruiz-Dayao Z. Acquired factor VIII inhibitor treated with cyclophosphamide, vincristine, and prednisone. Am J Hematol. 2002;69(4):294–295. doi:10.1002/ajh.10070
   PubMed Web of Science ®Google Scholar
• McFadyen JD, Tran H, Kaplan ZS. Factor VIII inhibitor eradication with bortezomib in acquired haemophilia A. Br J Haematol. 2017;178(6):986–987. doi:10.1111/bjh.14185
   PubMed Web of Science ®Google Scholar
• Ratnasingam S, Walker PA, Tran H, et al. Bortezomib-based antibody depletion for refractory autoimmune hematological diseases. Blood Adv. 2016;1(1):31–35. doi:10.1182/bloodadvances.2016001412
   PubMed Web of Science ®Google Scholar
• Zeitler H, Ulrich-Merzenich G, Hess L, et al. Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept. Blood. 2005;105(6):2287–2293. doi:10.1182/blood-2004-05-1811
   PubMed Web of Science ®Google Scholar
• Frade-Guanaes JO, Racanelli AP, Siqueira LH, et al. Acquired hemophilia A relapse is related to Th2 response, and increased expression of B-Cell Activating Factor (BAFF). Blood. 2021;138:497. doi:10.1182/blood-2021-152589
   Web of Science ®Google Scholar
• Sun B, Xue F, Feng Y, et al. Outcome of CARE: a 6-year national registry of acquired haemophilia A in China. Br J Haematol. 2019;187(5):653–665. doi:10.1111/bjh.16128
   PubMed Web of Science ®Google Scholar